Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch

Alphamab’s $100 million Series A last November for the oncology unit marked its first venture round in almost 10 years of existence. As it turned out, it was also a signal that founder and CEO Ting Xu was ready to bring in the cash flow he needs to complete the regulatory journey for his lead checkpoint inhibitor and dive into the bispecific project he’s envisioned for years.